Gut Microbiota And *Diabesity*: Role In Energy Harvest, Gut Barrier Integrity, Endocrine Modulation, And Metabolic Inflammation
===============================================================================================================================

Obesity is a complex, multifactorial disease characterized by an excessive accumulation of fat due to an imbalance between energy intake and expenditure. The linear rise in the prevalence of T2D throughout the normal, overweight and obese ranges is so high that the relative risks of diabetes are 40 times higher when BMI increases above 35 kg/m^2^ ([@B27]; [@B47]; [@B54]; [@B83]). The public concern over the obesity epidemic mostly lies in the intimate connection between obesity and T2D (so-called *diabesity*; [@B1]) and makes the elucidation of mechanisms underlying the co-occurrence of the two diseases a central focus of current biomedical research.

Recently, consideration has started to be given to the gastrointestinal tract as a key point in the development and progression of complex metabolic diseases, since it represents the milieu where interactions between exogenous (i.e., diet, microbiome) and endogenous (i.e., genetic) factors predisposed to disease and the body's defenses (physical barrier, immune system response) actually take place. Increasing evidence indicates in particular the impact of changes in the composition of the human gut microbiota on host metabolism and a variety of diseases ([@B2]; [@B48]; [@B66]).

Firmicutes (Gram-positive), Bacteroidetes (Gram-negative) and Actinobacteria (Gram-positive) represent over 90% of the phyla and dominate the gut microbiota ([@B14]), but a relevant change in their relative proportion has been described in obesity and T2D. A favorable prevalence of Firmicutes bacteria toward healthy subjects has been observed in both animal models of obesity ([@B40]) and human obesity ([@B41]; [@B74]), also reviewed in ([@B74]; [@B62]; [@B48]), although with some discrepancies among data ([@B64]). Although the potential impact of specific species on host metabolism has already been elucidated, most of the data so far available have reported observed changes at the phylum level. Furthermore, the physiological contribution of Firmicutes in the development of the obese phenotype is still being debated. In turn, some studies have observed a positive correlation between ratios of Bacteroidetes to Firmicutes and plasma glucose concentration, but not with BMI, although this was expected ([@B37]).

Different mechanisms have been proposed in the attempt to understand the impact of microbiota both in maintaining metabolic health and in the development of obesity and T2D. Essentially, the intestinal microbial variability has been hypothesized as an important factor in four different processes, namely: (i) the modulation of energy homeostasis by regulating the energy harvest from diet, fat storage, lipogenesis, and fatty acid oxidation (host energy metabolism; [@B72]; [@B50]); (ii) the modulation of the gut barrier integrity by regulating the epithelial permeability, the intestinal motility and the transport of digestion products such as short-chain fatty acids, which are an energy source for colonocytes ([@B61]); (iii) the regulation of gastrointestinal peptide hormone secretion, by suppressing the secretion of the lipoprotein lipase inhibitor (fasting-induced adipose factor), determining the release of fatty acids from circulating triglycerides and lipoproteins in muscle and adipose tissue and promoting fat mass accumulation ([@B3]); and (iv) the modulation of the host inflammatory state by contributing to the systemic increase of lipopolysaccharide, which impairs insulin sensitivity (metabolic endotoxemia; reviewed in [@B3]; [@B9], [@B10]; [@B68]; [@B76]; [@B65]). Evidence of the role of gut microbiota in the preservation of metabolic health also comes from the effect of prebiotics, such as non-digestible carbohydrates, namely non-digestible ingredients that are fermented by specific beneficial bacterial strains, selectively promote the growth and/or activity (release of end-products of bacterial fermentation) of the gastrointestinal microbiota, affecting favorably the host health ([@B20]). The intake of prebiotics has in fact been described to act on host endocrine secretion, improve gut barrier integrity by increasing the release of glucagon-like peptide-2 ([@B10]; [@B13]), stimulate postprandial release of peptides involved in energy homeostasis and/or pancreatic functions such as the anorexigenic glucagon-like peptide-1 and peptide YY, and the decrease of orexigenic peptides such as ghrelin in plasma which in turn modulates food intake (regulators of appetite) and energy expenditure across the entire gastrointestinal tract ([@B53]; [@B12]; reviewed in [@B76]). Furthermore, evidence suggests that the modulation of the host metabolic health by prebiotics intake can be mediated to specific fermentation products (i.e., short-chain fatty acids, predominantly acetate, propionate and butyrate) produced by cross-feeding between *Eubacterium rectale* and *Bifidobacterium thetaiotaomicron* ([@B75]); *Propionibacterium* sp. and *Bacteroides* sp. ([@B26]); *Faecalibacterium prausnitzii* and *Roseburia intestinalis/Eubacterium rectale* ([@B17]; [@B75]) respectively.

The Metabolomic Approach
========================

Due to the species specificity of several enzymatic machineries, the gut microbial composition and activity are likely to be characterized by the profile of small metabolites produced in the intestinal lumen, eventually absorbed through the intestinal barrier and further biotransformed by the host. Consequently, the complexity of microbial--host exchanges may be reflected in the specific chemical signature of host circulating biofluids ([@B52]). Metabolomics has recently attracted attention as the most suitable -*omics* technology for investigating complex, polygenic and multifactorial diseases with a strong metabolic etiology, such as obesity and T2D as well as the crosstalk of distinct predisposing factors in disease development and progression ([@B18]; [@B43]; [@B15]; [@B35]). Aimed at the comprehensive analysis of the low- molecular- weight compounds contained in a biological system --by definition, metabolites comprise a plethora of primary or secondary derivatives of the intermediate metabolism (molecular weight below 900 and 2000 Dalton, depending on sources; [@B4]; [@B56]; [@B23]) metabolomics represents a powerful tool for exploring the crosstalk between the microbial and host metabolism in a more exhaustive fashion.

The workflow applied in metabolomic studies is broadly categorized into five main steps: (1) sample collection, (2) sample preparation, (3) data acquisition, (4) data analysis, and (5) biological interpretation of the results obtained ([@B43]). The analytical techniques most commonly used for the characterization of the metabolome of a biological sample are MS and ^1^H-NMR. Both technologies have their advantages and disadvantages. ^1^H-NMR implies a non-destructive, non-selective, cost-effective, and relatively sensitive analysis while, compared to ^1^H-NMR, MS mainly offers potential advantages in terms of sensitivity and, if coupled to different separation techniques such as LC or GC, it provides a means of detecting a broader and complementary range of biomarkers ([@B18]). LC coupled to electrospray ionization MS is becoming the method of choice for the acquisition of profiling metabolites in complex biological samples ([@B63]) through both targeted (i.e., triple quadrupole-driven) and non-targeted (e.g., quadrupole time-of-flight-, linear trap quadrupole orbitrap-driven) approaches.

The present review aims to summarize the gut microbial--host cometabolites identified so far in humans in relation to obesity and/or T2D by targeted and untargeted metabolomic studies. Since the potential impact of some specific species in host metabolism has already been elucidated, an attempt to associate bacterial producers of the co-metabolites with the metabolic alterations related to the obese, diabetic, or diabese phenotype was also made. A critical view of the current limitations and future directions of metabolomics will accompany the discussion.

Materials and Methods {#s1}
=====================

Search Strategy
---------------

The following keywords were searched for in the PubMed and Web of Science electronic databases: (Metabolom^∗^ \[TW\] or co-metabol^∗^ \[TW\] or host-gut metabo^∗^ \[TW\] or nuclear magnetic resonance \[TW\] or MS \[TW\] or magnetic resonance spectroscopy \[TW\]) AND (OBES^∗^ \[TW\] OR DIABET^∗^ \[TW\] OR DIABES^∗^ \[TW\]) AND (gut micro^∗^ \[TW\]). Species (human), language (English), and publication date restrictions (2000 to date, last search on November 27th, 2014) were imposed, but there were none for gender, age or ethnicity. Relevant references cited in the selected articles were additionally reviewed. Targeted and untargeted metabolomic approaches driven by ^1^H-NMR or MS techniques were both included in the selection. Low-molecular-weight (\<1000 Da) metabolites significantly up- or downregulated in overweight and obese subjects with/without impaired glycemic control, with respect to controls (i.e., lean, healthy subjects), were the primary outcomes of interest of the review.

Results And Discussion
======================

Characteristics of the Studies and Metabolic Variations
-------------------------------------------------------

Only eight human studies successfully met the eligibility criteria for inclusion in the review (details in the Supplementary Material File). As summarized in **Table [1](#T1){ref-type="table"}**, seven observational and one interventional study have so far applied a metabolomic approach and specifically identified changes in products of the gut microbial--host co-metabolism in overweight to obese individuals (BMI \> 25 kg/m^2^) and/or several degrees of impaired glycemic control (ranging from IGT up to T2D) compared to control individuals. Other comorbidities were not described (i.e., hypertension, renal or liver dysfunction).

###### 

Human metabolomic studies showing gut microbial--host co-metabolites significantly altered in obese and/or T2D diagnosed patients, respect to controls.

  Observational Studies                                                                                                                                                                                                                                                                                                                                                                                             
  -------------------------------------------------------------------------------------------- ----------------------------------------------------- ------------------------------------------------------------------------------ ------------------------------------- ---------------------------------------------------- ------------------------------------------------------------------------------------ ---------------
  Obesity + pre-T2D                                                                            Group 1 = 15 (0F) morbidly OB with IR                 No                                                                             Non-targeted                          Spot urine, fasting                                  ↓Hippuric acid, *N-* methylnicotinate aaa 2-hydroxyisobutyrate                       [@B7]
                                                                                               Group 2 (CT) = 10 (0F) healthy NW (with NGT)          No                                                                             (^1^H-NMR)                                                                                                                                                                      
  Obesity + T2D (treated vs. not)                                                              Group 1 = 15 (8F) OW with treated T2D                 Metformin (15)                                                                 Non-targeted                          Serum, fasting                                       aaaTrimethylamine-*N*-oxide                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                               Group 2 (CT) = 20 (10F) OB with untreated T2D         No                                                                             (^1^H-NMR)                                                                                                                                                                      
  Obesity + T2D (treated vs. not)                                                              Group 1 = 20 (11F) OB with treated T2D                Glyburide (10), glimepiride (6), Gliclazide (4)                                Targeted                              Spot urine, fasting                                  ↓Hippuric acid (untreated T2D) aaahippuric acid (with anti-T2D drugs)                [@B30]
                                                                                               Group 2 = 20 (11F) OB with untreated T2D              No                                                                             (UPLC-MS)                                                                                                                                                                       
                                                                                               Group 3 (CT) = 20 (10F) healthy OB (with NGT)         No                                                                                                                                                                                                                                                             
  Obesity + T2D                                                                                Group 1 = 30 (13F) OW to OB with untreated T2D        No                                                                             Non-targeted                          Spot urine, fasting                                  ↓Hippuric acid, *N-* methylnicotinate, ↓*N,N*-dimethylglycine, *N,N* dimethylamine   [@B60]
                                                                                               Group 2 (CT) = 12 (4F) healthy NW to OW (with NGT)    No                                                                             (^1^H-NMR)                                                                                                                                                                      
  Obesity + T2D                                                                                Group 1 = 40 (0F) OB with T2D                         No (7), antidiabetic medication                                                Targeted                              Serum, fasting                                       ↓Cholate aaadeoxicholate ↓Gamma muricholate                                          [@B67]
                                                                                               Group 2 (CT) = 60 (0F) healthy OW (with NGT)                                                                                         (UPLC-MS/MS)                                                                                                                                                                    
  (pre-)T2D                                                                                    Group 1 = 74 (42F) NW with T2D                        No (48), metformin, acarbose, glipizide or repaglinide as a monotherapy (26)   Non-targeted                          Serum, fasting                                       ↓Choline (vs. NGT and vs. IGT)                                                       [@B85]
                                                                                               Group 2 = 77 (44F) NW with IGT                        No                                                                             (^1^H-NMR)                                                                                                                                                                      
                                                                                               Group 3 (CT) = 80 (46F) healthy NW (with NGT)         No                                                                                                                                                                                                                                                             
  Obesity + pre-T2D                                                                            Group 1 = 12 (?F) OB with IGT                         No                                                                             Non-targeted                          Plasma, fasting                                      aaaGlycochenodeoxycholic acid                                                        [@B86]
                                                                                               Group 2 (CT) = 39 (?F) healthy OB (with NGT)                                                                                         (UPLC-qToF-MS)                        Spot urine, fasting                                  ↓Hippuric acid, 3-hydroxyhippuric acid, methyluric acid, methylxanthine              
                                                                                                                                                                                                                                                                                                                                                                                                                    
  **Single-arm intervention study (weight-loss plan with calorie restriction and exercise)**                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                    
  **Disease**                                                                                  **Participants**                                      **Duration and associated clinical outcomes**                                  **Approach (analytical technique)**   **Specimen**                                         **Changes from baseline**                                                            **Reference**
                                                                                                                                                                                                                                                                                                                                                                                                                    
  Obesity + pre-T2D                                                                            Group = 15 (15F) OB with IR (only 12 up to the end)   0, 14--17 weeks ↓BMI, body fat, V02, fasting                                   Non-targeted (GC-ToF-MS)              Plasma, fasting and 30, 60, 90, 120 min after OGTT   aaaTricarballylic acid (fasting and after OGTT)                                      [@B8]
                                                                                                                                                                                                                                                                                                                                                                                                                    

1

'healthy' stands for NGT subjects. Abbreviations: F, number of females in studies; CT, control; BMI, Body Mass Index; OW, overweight; OB, obese; NW, normal weight; NGT, normal glucose tolerance; IGT, impaired glucose tolerance; IR, insulin resistance; T2D, type 2 diabetes; pre-T2D, prediabetes;

1

H NMR, proton nuclear magnetic resonance; UPLC-qTOF-MS, reversed-phase ultra performance liquid chromatography coupled to electrospray ionization quadrupole time-of-flight mass spectrometry; UPLC-MS/MS, ultra-performance liquid chromatography tandem mass spectrometry; GC-TOF-MS, gas chromatography/time-of-flight mass spectrometry.

2

Medication during the study.

Overall, the study subjects, designs and objectives were quite heterogeneous despite the small number of retrieved studies (Supplementary Material File), thereby complicating an otherwise integrated and consistent picture of the metabolomic changes observed.

Urine ([@B60]; [@B7]; [@B86]; [@B30]), fasting serum ([@B29]; [@B85]; [@B67]) and plasma ([@B86]; [@B8]) were the biological samples used in these studies. A data-driven untargeted approach was chosen in the majority of the studies ([@B60]; [@B29]; [@B85]; [@B7]; [@B86]; [@B8]) while two of them provided quantitative information about known targeted metabolites ([@B67]; [@B30]). The metabolic changes observed in these studies and the related interpretations are summarized in **Table [2](#T2){ref-type="table"}.**

###### 

Summary of the most significant gut microbial and host co-metabolites identified in the selected studies.

  Class                                  Metabolite                                                  Disease               Change^1^   Anti-T2D drugs effect   Sample         Interpretation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Reference                       *Related bacteria (phyla)*
  -------------------------------------- ----------------------------------------------------------- --------------------- ----------- ----------------------- -------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------- --------------------------------------------------
  Bile acids (primary)                   γ-muricholate (hyocholate) cholate glycochenodeoxycholate   Obesity + T2D         ↓                                   Blood fluids   Bile acids are proposed as new metabolic integrators of whole body energy homeostasis that influence glucose and lipid metabolism. Subjects with diabetes exhibit alterations in the composition of the bile acid pool and their related biosynthetic pathway. A higher rate of conversion of primary to secondary bile acids by the gut microbiota has been implicated in the observed variation.                                                                                                                                                                                                                                                                                                                                                                                                                 [@B67]                          Firmicutes^3^
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                     Obesity + T2D         ↓                                   Blood fluids                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      [@B67]                          
                                                                                                     Obesity + pre-T2D     aaa                                 Blood fluids                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      [@B86]                          
  Bile acids (secondary)                 Deoxycholate                                                Obesity + T2D         aaa                                 Blood fluids                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      [@B67]                          
  Vitamin metabolites                    Choline                                                     (pre-)T2D             ↓↓^2^                               Blood fluids   In the absence of anti-T2D treatment, alteration of choline metabolism (increased degradation) noticed in T2D patients may result from: (a) an altered demand, possibly by altered lipoprotein turnover/biosynthesis, (b) an altered gut microbiotal activity associated with T2D development, or (c) an osmotic compensation for raised blood glucose concentrations. Low levels of choline would also associate to the prevalence of OB/T2D complications, namely nonalcoholic fatty liver. When associated with metformin, may indicate a possible two-way relationship between the anti-T2D treatment and the gut microbiota. The intestinal bacteria composition would influence glucose metabolism and the mechanisms of action of metformin, and the drug would regulate back the gut microbial function.   [@B85]                          Firmicutes, Proteobacteria and Actinobacteria^4^
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                         TMAO                                                        Obesity + T2D                     aaa                     Blood fluids                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      [@B29]                          
                                         DMA, DMG                                                    Obesity + T2D         aaa                                 Urine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             [@B60]                          
                                         *N*-methylnicotinate (trigonelline)                         Obesity + (pre-)T2D   ↓                                   Urine          Gut microbial class-specific product of the metabolism of niacin, which is an essential vitamin involved in major physiological functions such as coenzyme in tissue respiration, carbohydrate and lipid metabolism. Trigonelline regenerates glutathione stores that are depleted by oxidative stress in obesity. Moreover, low levels of trigonelline could suggest perturbation in nucleotide metabolism during T2D.                                                                                                                                                                                                                                                                                                                                                                                            [@B60]; [@B7]                   NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Organic acids and derivates            2-hydroxyisobutyric acid                                    Obesity + pre-T2D     aaa                                 Urine          Since their production is species specific at the colonic level, changes in their level may reflect (a) significant shifts in the subjects' gut microbe ecology or functional differences in the microbiome metabolic activity between OB with IR and healthy lean individuals and (b) changes in the host metabolism/uptake of gut-derived metabolites, possibly related to a variation in the intestinal mucosa permeability after weight-loss plan with calorie restriction and exercise.                                                                                                                                                                                                                                                                                                                       [@B7]                           Firmicutes^5^
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                         tricarballylic acid                                         Obesity + pre-T2D     aaa                                 Blood fluids                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      [@B8]                           
  Phytochemical and purine metabolites   hippuric acid                                               Obesity + (pre-)T2D   ↓↓↓↓        aaa                     Urine          Changes in the production of hippurate and derivatives are generally connected to diet and gut microbial activities with the human metabolic phenotype and the blood pressure of individuals. They could indicate a relevant role of the gut microbiota in the pathogenesis of the pre-T2D state and could be related to age progression and gender effects on metabolism in T2D. The reversion of these changes by sulfonylurea treatment would confirm a beneficial effect of anti-T2D drugs on gut microbiota metabolism, besides glucose homeostasis. Higher concentrations in obese humans could reflect the known role of gut microbiota in energy metabolism and immune function of the host.                                                                                                               [@B60]; [@B7]; [@B86]; [@B30]   Firmicutes^5^
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                         3-Hippuric acid hydroxyhippuric acid                                                                                  Urine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             [@B86]                          
                                         Methyluric acid                                             Obesity + pre-T2D     ↓                                   Urine          Gut microbiota-associated metabolite biomarkers, related to IGT. Accumulating evidence indicates that the gut microbiota is instrumental in the energy metabolism and immune function of the host.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 [@B86]                          NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                         Methylxanthine                                              Obesity + pre-T2D     ↓                                   Urine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             [@B86]                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

OB, obesity; T2D, type 2 diabetes; IGT, impaired glucose tolerance; NGT, normal glucose tolerance; SU, sulfonylurea; M, metformin hydrochloride; TMAO, trimethylamine-

N

-oxide; NMN, ox

N

-methylnicotinate; DMG,

N, N

dimethylglycine; DMA, dimethylamine.
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In respect to healthy controls.
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Also in T2D vs. IGT but not IGT vs. NGT.
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Co-metabolism of Bile Acids
---------------------------

Two of the metabolomic studies described in this review highlighted a change in the circulating pool of BA in obese patients with insulin resistance or T2D, compared with BMI-matched healthy individuals ([@B67]; [@B86]). Alterations involved both human-derived (hepatic) structures (primary BA) and gut microbial-produced derivatives (secondary BA).

To the best of our knowledge, it is currently accepted that the bacterial enzymes involved in the biotransformation from primary to secondary BA are not shared across the whole microbial community, although they have been described so far in genera belonging to the four major phyla Firmicutes, Actinobacteria, Bacteroidetes and Proteobacteria ([@B36]). Furthermore, according to [@B31] Actinobacteria and Firmicutes clones would be the only ones able to degrade all conjugated BA, with Bacteroidetes species being limited to tauro- conjugation activities.

After their production in the liver and the eventual glyco- and tauro-conjugation (*N*-acyl amidation with glycine or taurine substituents), primary BA are secreted in the small intestine through the bilis ([@B58]; [@B25]; [@B69]), where they are first subjected to deconjugation by a bacterial bile salt hydrolase enzyme produced by species of the four phyla, such as *Clostridium, Bacteroides, Lactobacillus, Bifidobacterium*, and *Enterococcus* ([@B5]). In the ileum, more than 95% of these BA undergo enterohepatic recycling ([@B69]; [@B34]; [@B52]), are absorbed from the intestine and returned to the liver ([@B58]). The remaining 5% escape the enterohepatic circulation and reach the large bowel where the bioconversion into secondary BA is completed, especially by Firmicutes phyla *(Eubacterium* sp. and *Clostridium* sp.; [@B46]; [@B51]; [@B69]).

A decrease of primary BA and an increase of secondary BA was observed in the fasting serum of overweight patients with T2D, compared to healthy subjects ([@B67]). The authors hence concluded that differences in the gut microbiota of diabetic patients may lead to higher rates of conversion from primary to secondary BA. In turn, [@B86] only observed an increase of glycochenodeoxycholic acid (primary BA) in the plasma of prediabetic individuals, while no changes were noticed in urine. Despite the only partial overlapping of the results, both studies suggested that overweight and obesity may not be the predominant factor implied in the metabolomic changes observed, and thus in linking impaired glucose homeostasis to alterations in BA pool composition. As argued in those studies, the variation of the BA pool in biofluids may depend on different factors, namely a change in the prevalence or activation of the gut microbial species implied in BA bioconversion or an altered reabsorption of BA through the gut mucosa, in turn produced by the disease itself, by dietary or other external changes (i.e., induced by bariatric surgery), or by a combination of these. In any case, the results indicated a probable implication of the modulation of BA biosynthetic pathways in the relationship between gut microbiota and insulin resistance (**Figure [1](#F1){ref-type="fig"}**).

![**Products of bile acids co-metabolism associated with obesity and diabetes via metabolomic studies.** After the ingestion of food, conjugated BA are secreted into the intestinal lumen, are subjected to deconjugation by the intestinal bacteria, and converted to secondary BA. The main effect of secondary BA is mediated by the FXR activation, which in turn act increasing insulin secretion and sensitivity in the pancreas. Primary BA is also involved in glucose metabolism by TGR-5 activation and glucagon-like peptide-1 (GLP-1) release. Host endogenous processes are in solid lines, while microbial production and metabolite actions are in dotted lines.](fmicb-06-01151-g001){#F1}

These findings are in line with independent studies that recently associated changes in BA turnover with *diabesity*. In turn, a reduction of the bacterial enzymatic activities involved in the conversion of primary into secondary BA was observed in diabetic patients compared to healthy controls, and linked to Firmicutes phyla ([@B36]). A very similar pattern was also reported in obese patients with diagnosed metabolic syndrome, treated with antibiotic agents (vancomycin and amoxicillin) and associated with both a decreased prevalence of the Firmicutes population and a reduction of peripheral insulin sensitivity ([@B77]). Taken together, these data suggest a possible link between BA and metabolic health ([@B38]). In line with these findings, BA have recently been proposed as metabolic integrators of whole-body energy homeostasis implicated in the regulation of various metabolic pathways, including their own synthesis and enterohepatic circulation, triglyceride, glucose, and energy homeostasis, by acting as signaling molecules through receptor-dependent and -independent pathways. The role of a dysregulation of this BA-mediated metabolic control in the pathogenesis of T2D and co-morbidities, such as its attractiveness as a therapeutic target, is now beginning to be elucidated (reviewed in [@B55]). Their action on energy metabolism regulation would occur via both the activation of the nuclear receptor FXR and FXR-independent pathways, such as through the membrane receptor TGR5 expressed in several tissues including gall bladder, ileum, colon, and brown and white adipose tissue.

It is worth noting that preliminary evidence has shown that not all BA activate equally, and the microbial-derived production of secondary BA could be an important mechanism in the regulation of signaling pathways involved in the development of *diabesity* ([@B51]). When gut microbial-derived secondary BA are bound to TGR5, the receptor is internalized and a series of adenylate cyclase-dependent signaling is triggered by activating distinct pathways involved in glucose and lipid energy metabolism ([@B32]; [@B71]). In tissues, such as brown adipose tissue and muscle, this would lead to an increased mitochondrial activity and oxidative phosphorylation, which has been linked to an insulin sensitization both in genetic and diet-induced models of *diabesity* ([@B80]). In enteroendocrine L-cells ([@B32]), in turn, these signaling pathways would enhance glucose metabolism by stimulating the production of glucagon like peptide, thereby promoting insulin secretion. Finally, recent studies have also shown that BA secretion improves insulin secretion, insulin sensitivity and whole-body glucose homeostasis (reviewed in [@B71]), improving liver and pancreatic function in obese mice ([@B70]; [@B73]).

Co-metabolism of Vitamins
-------------------------

Products of the gut microbiota-driven metabolic pathway of vitamins such as choline and niacin have been associated with obesity and diabetes.

### Choline Metabolism

Although humans may produce choline endogenously (*de novo* hepatic synthesis), dietary intake (e.g., from egg yolk, liver, muscle meats, fish, nuts, legumes) is necessary to meet the demand for body health maintenance ([@B6]; [@B84]). Once dietary choline reaches the intestine, anaerobic intestinal microorganisms, mainly of Firmicutes and Proteobacteria phyla ([@B59]) catalyze its conversion to TMA, which may be further degraded to several methylamines by the gut microbiota (sym-xenobiotic pathway; [@B24]), or is absorbed and oxidized to TMAO by the hepatic FMO3 enzyme. Choline may also be converted into betaine and further products (e.g., dimethylglycine) by mammalian mitochondrial pathways in the liver and kidney ([@B39]) (**Figure [2](#F2){ref-type="fig"}**). The bacterial gene clusters responsible for anaerobic choline degradation started to be identified only recently. Bacterial species belonging to Firmicutes, Actinobacteria and Proteobacteria phyla have been revealed as possessing the necessary enzymatic activities, while Bacteroidetes would be apparently deprived ([@B11]). However, the complete diversity of species that contribute to TMAO production in humans still remains unknown ([@B59]).

![**Products of vitamin, phytochemical and purine co-metabolism associated with obesity and diabetes via metabolomics studies.** Intestinal microorganisms catalyze the conversion of dietary choline and carnitine into TMA with a direct effect on the intestinal mucose (increased oxidative stress) and is the substrate for the hepatic production of TMAO (associated with cardiovascular disease risk) and TMA. Choline may escape microbial degradation and convert into betaine and further products \[i.e., dimethylglycine (DMG)\] by mammalian mitochondrial pathways in the liver and kidney where they have an detrimental osmotic effects. For most of the host microbial co-metabolites associated with the diabese phenotype, the eventual role in glucose and lipid metabolism remains unknown. OGTT, Oral glucose tolerance test; SAH and SAM, *S*-adenosylmethionine to *S*-adenosylhomocysteine (methionine cycle).](fmicb-06-01151-g002){#F2}

Recent studies have shown that circulating levels of choline and TMAO are related to cardiovascular disease risk ([@B16]; [@B45]; [@B78]; [@B33]; [@B79]), and the gut microbiota-driven TMA-FMO3-TMAO pathway has been particularly recognized as a key regulator of lipid metabolism and inflammation. Increased levels of TMAO have been observed in a leptin-deficient murine model of obesity and T2D ([@B21]; [@B82]) and revealed a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice ([@B16]). The systemic perturbations of key metabolites of choline have also been related to the progression of T2D, suggesting that in the early stages of diabetes an attenuated conversion of choline into dimethylglycine may occur, which can be observed by the increased levels of TMAO and TMA, with a reversion of this behavior at a later stage of the disease ([@B22]).

[@B44] published the first study linking TMAO and T2D in humans. Using a^1^H-NMR approach, increased levels of TMAO and dimethylamine were observed in the urine of diabetic individuals compared to a group of healthy individuals, and were present in high concentrations even in diabetics with good metabolic control (i.e., absence of glycosuria and glycohemoglobin). In the last decade, little progress has been made on the mechanisms that would directly or indirectly involve TMAO in the development of diabetes. Nevertheless, the potential role of an altered composition of the microbiota and its ability to metabolize choline in glucose homeostasis and disease development has become increasingly relevant ([@B16]).

To the best of our knowledge, three further metabolomic studies observed a change in choline metabolism, which was associated with impaired glycemic control in humans, within a wide range of BMI ([@B60]; [@B29]; [@B85]; **Table [1](#T1){ref-type="table"}**). In all of them, fasting biosamples were analyzed, thereby avoiding fluctuations in choline concentrations due to dietary intake. [@B60] carried out a ^1^H-NMR-driven metabolomic comparison of urinary changes linked to T2D both in animals (obese mice and rats with autosomal recessive defects in the leptin receptor gene -- *db/db* and Zucker *fa/fa*, respectively), and individuals who were overweight to obsese (BMI = 25--40) compared to healthy lean controls. An increased excretion of a product of choline biotransformation, namely *N,N*-dimethylglycine and *N,N*-dimethylamine, distinguished the urinary metabolome of T2D in all species in the study ([@B60]), suggesting a possible increase in the choline turnover. The authors assumed that the *diabese* phenotype may have a major demand for choline, possibly due to an altered biosynthesis of lipoproteins, an altered metabolism of methylamines -- which would play an important osmoregulatory role by degrading dietary choline -- or to an altered intestinal microbiota composition ([@B60]). Although there is a scarcity of data in this regard, Firmicutes and Proteobacteria seem to be the most implicated phyla in the conversion of choline to TMAO ([@B59]). For this reason, the decline of choline circulating levels and increase of choline subproducts such as TMAO and DMA in obese subjects would be in line with the increase of the Firmicutes phylum associated with obese phenotype ([@B41]).

The role of BMI in the observed association was partly downsized in a second study ([@B85]). By applying a similar untargeted and ^1^HNMR-driven approach, in fact, [@B85] demonstrated a decrease in the serum levels of choline in normal-weight subjects with T2D (BMI = 25.9 ± 9.0) compared to non-diabetic lean individuals (normal or IGT); however, no changes in the downstream products of choline metabolism were detected. Aside from increased insulin resistance, the decrease in serum choline is linked to a specific shift in the gut microbial community in the diabetic patients (relative increase in Firmicutes) and to an increase in the prevalence of T2D complications, as NAFLD ([@B85]). The role of the microbial community hosted by *diabese* subjects in altering choline metabolism was also tested by assessing the effects of antidiabetic medication ([@B29]). As shown in **Table [1](#T1){ref-type="table"}**, [@B30] observed increased serum levels of TMAO in overweight diabetic subjects receiving metformin treatment *versus* untreated *diabese* controls, which may indicate an intestinal bacterial regulation function of metformin. It has already been suggested that antidiabetic treatments have a beneficial effect on gut microbiota metabolism ([@B30]), although the exact mechanisms are still unclear ([@B49]). The authors suggested a link between the deregulation of choline metabolism in T2D and a rupture of the intestinal barrier by oxidative stress ([@B81]). In any case, a possible two-way relationship between anti-T2D treatment and gut microbiota has been hypothesized.

### Niacin Metabolism

Alterations in the niacin (vitamin B3) metabolism have also been observed in association with obesity and T2D, and due to the overlapping in the choline/niacin catabolic pathways (i.e., via betaine and glycine metabolism), may also reflect a dysregulation in choline metabolism ([@B28]). Through a LC--MS-driven metabolomic approach, an altered urinary excretion of nicotinuric acid (*N*-nicotinoyl-glycine) was recently proposed as a potential marker of metabolic syndrome diagnostic traits and of cardiometabolic risk ([@B28]). Similarly, an association between the presence of trigonelline (betaine nicotinate) and obese and diabetic phenotypes has been proposed. Despite having a possible exogenous (dietary) origin, trigonelline is mostly biosynthesized by the gut microbiota during the conversion of *S*-adenosylmethionine to *S*-adenosylhomocysteine (methionine cycle). By applying a ^1^H-NMR-based metabolomics approach, [@B60] found lower levels of trigonelline in the urine of diabetic (*db/db*) mice and humans, associated with a change in energy and tryptophan metabolism. Further animal ([@B60]; [@B82]) and human studies ([@B7]) confirmed a decline of trigonelline in obesity and diabetes, some authors suggesting that oxidative stress possibly has a role (i.e., via glutathione store depletion) in the observed relationship ([@B7]). Trigonelline is known to be involved in major physiological functions including lipid and carbohydrate metabolism.

Co-metabolism of Organic Acids and Derivates
--------------------------------------------

[@B7] identified high levels of 2-hydroxyisobutyrate in the urine of obese people, and the change was associated with a reduced bacterial diversity in 'obese' gut microbiota possibly involved in nutrient and energy harvest (**Tables [1](#T1){ref-type="table"}** and **[2](#T2){ref-type="table"}**). In particular, 2-hydroxyisobutyrate is a product of the microbial degradation of dietary proteins that escape digestion in the upper gastrointestinal tract, and its production has been associated with the presence of specific microbial members such as *Faecalibacterium prausnitzii* ([@B42]), butyrate-producer species with anti-inflammatory effect and to be in low levels in obese and *diabese* individuals compared to healthy subjects ([@B57]). In addition, [@B8] observed that obese subjects involved in a dietary weight loss program had higher levels of tricarballylic acid after an OGTT compared with the fasting concentrations. Interestingly, tricarballylic acid is a product of gut microbial metabolism of food-derived trans-aconitate, described as an additive contained in the OGTT solution. Once again, the authors suggested a two-way relationship between the obese and gut microbial phenotype (tricarballylic acid production would in turn increase the metabolic activity of specific gut microbes associated with its production).

Co-metabolism of Phytochemicals and Purines
-------------------------------------------

Hippuric acid and 3-hydroxyhippuric acid are two normal urinary components mainly derived from the degradation of plant (poly)phenols and aromatic amino acids (i.e., phenylalanine and tryptophan) by a range of gut microbes, recently found to belong to *Clostridium* sp. ([@B42]). The resulting benzoic acid is then absorbed, subjected to glycine conjugation reaction (by mitochondrial glycine *N*-acyltransferase) and finally excreted in urine ([@B30]). Decreased levels of hippuric acid ([@B60]; [@B7]; [@B86]) and 3-hydroxyhippuric acid in urine have been related to IGT and obesity ([@B86]) in both animal and human studies. In turn, the downregulation was reduced in T2D patients after the treatment with sulfonylurea, suggesting the drug potentially has a protector effect on gut microbiota metabolism ([@B30]). However, a strict dietary assessment is mandatory to dismiss any diet-dependent variation among groups, due to the wide range of phenolic compounds leading to these last-step metabolites following microbial and human biotransformations (lack of specificity; [@B60]). Moreover, the reasons for their putative associations with obesity and T2D are unknown. [@B60] suggested that hippurate could be related to age progression and gender effects on metabolism in T2D, but these suppositions need to be further investigated.

[@B86] observed that subjects with IGT had a reduced excretion of methyluric acid and methylxanthine, which are products of the microbial metabolism of methylxanthines contained for instance in coffee and tea. The authors tentatively interpreted the observed changes as the result of an altered gut microbiota in the presence of insulin resistance, although their putative role in glucose metabolism is still unknown.

Conclusion
==========

Current public health burdens such as obesity and T2D are complex, polygenic, multifactorial diseases with a strong metabolic etiology. Gut microbiota have recently been proposed as a crucial environmental factor in their development, but the metabolic complexity of the symbiotic interaction between the host individual and its microbial community, as well as the impact of this crosstalk between body weight changes and glucose homeostasis, are still unclear.

However, our review highlighted how few metabolomic studies have been specifically conducted so far to identify the role of the gut microbiota in the development and progression of obesity and T2D, at least in humans.

Despite the scarcity, heterogeneity and intrinsic limitations of the metabolomic studies conducted so far aimed at identifying the role of the gut microbiota in the development and progression of obesity and T2D (i.e., wide range of BMI and/or glycemic status evaluated, important sources of variability not considered including ethnic, gender effects, and dietary assessments), the results obtained by these data-driven metabolomic approaches are in line with findings independently obtained from *in vitro* or animal model studies. Products of the microbial/host metabolism of BA, vitamins (choline, niacin), branched fatty acids, purines and phenolic compounds have been described as being altered in (pre-)diabetic subjects, with or without increased BMI, compared with healthy controls. Moreover, few articles show a clear relation between metabolites and their bacterial producers in terms of the complexity of the gut microbiota and the cross-feeding mechanisms that would have combined bacterial effects in the colon ecosystem.

More efforts should be directed in the future toward expanding our knowledge of the metabolic interactions of the host and the gut microbiota, particularly through a strict evaluation of the lifestyle factors (i.e., diet) strongly involved in the modulation of this crosstalk.
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^1^H-NMR

:   proton nuclear magnetic resonance

BA

:   bile acids

IGT

:   impaired glucose tolerance

FMO3

:   flavin monooxygenase 3

FXR

:   Farnesoid X Receptor

GC

:   gas chromatography

LC

:   liquid chromatography

MS

:   mass spectrometry

NAFLD

:   non-alcoholic fatty liver disease

OGTT

:   oral glucose tolerance test

T2D

:   type 2 diabetes

TGR-5

:   *G*-protein coupled receptor

TMA

:   trimethylamine

TMAO

:   trimethylamine *N*-oxide.
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